Dynamic changes of HBV quasispecies and deletion patterns in a chronic hepatitis B patient

Journal of Medical Virology

Volumn 81, Issue 9, 2009, Pages 1551-1559

  Ji, Fen ^a,b   Zhou, Li ^c   Ma, Sufang ^a,b   Li, Feifei ^a,b   Ding, Huiguo ^c   Zeng, Changqing ^a  

^a Chinese Academy of Sciences   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Adefovir dipivoxil; Epitope; Hepatitis B virus; Lamivudine

Indexed keywords

ADEFOVIR DIPIVOXIL; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; VIRUS DNA;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CASE REPORT; CHRONIC HEPATITIS; DNA SEQUENCE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENE DELETION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MOLECULAR EVOLUTION; NONHUMAN; NUCLEOTIDE SEQUENCE; SPECIES DISTRIBUTION; TREATMENT FAILURE; WILD TYPE;

ADENINE; ANTIVIRAL AGENTS; CLUSTER ANALYSIS; DNA, VIRAL; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PHOSPHONIC ACIDS; PHYLOGENY; SEQUENCE ANALYSIS, DNA; SEQUENCE DELETION; SEQUENCE HOMOLOGY; VIRAL PROTEINS;

HEPATITIS B VIRUS;

EID: 68949148878     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21595     Document Type: Article

References (26)

1. Akarca US, Lok AS. 1995. Naturally occurring core-gene-defective hepatitis B viruses. J Gen Virol 76:1821-1826.
2. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD. 1998. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 27:1670-1677. (Pubitemid 28264693)
3. Angus P, VaughanR,Xiong S,YangH,DelaneyW,Gibbs C, Brosgart C, Colledge D, Edwards R, Ayres A, Bartholomeusz A, Locarnini S. 2003. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125:292-297. (Pubitemid 36929407)
4. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy KR, Johnson LC, Bunzendahl H, Condreay LD, Tzakis AG, Schiff ER, Brown NA. 1997. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349: 20-22. (Pubitemid 27022987)
5. Beasley RP. 1988. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 61:1942-1956.
6. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. 1995. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 333:1657-1661. (Pubitemid 26001954)
7. Fan YF, Lu CC, Chen WC, Yao WJ, Wang HC, Chang TT, Lei HY, Shiau AL, Su IJ. 2001. Prevalence and significance of hepatitis B virus (HBV) pre-S mutants in serum and liver at different replicative stages of chronic HBV infection. Hepatology 33:277-286.
8. Gunther S, Piwon N, Jung A, Iwanska A, Schmitz H, Will H. 2000. Enhanced replication contributes to enrichment of hepatitisBvirus with a deletion in the core gene. Virology 273:286-299. (Pubitemid 30641370)
9. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M,Marcellin P, Lim SG, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 348:800-807. (Pubitemid 36245756)
10. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Arterburn S, Xiong S, Currie G, Brosgart CL. 2005. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 352:2673-2681. (Pubitemid 41007822)
11. Hsieh YH, Su IJ, Wang HC, Chang WW, Lei HY, Lai MD, Chang WT, Huang W. 2004. Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage. Carcinogenesis 25:2023-2032. (Pubitemid 39405923)
12. Lavanchy D. 2004. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11:97-107. (Pubitemid 38365759)
13. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, Jeffers L, Goodman Z, Wulfsohn MS, Xiong S, Fry J, Brosgart CL. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigenpositive chronic hepatitis B. N Engl J Med 348:808-816. (Pubitemid 36245757)
14. Marinos G, Torre F, Gunther S, Thomas MG, Will H, Williams R, Naoumov NV. 1996. Hepatitis B virus variants with core gene deletions in the evolution of chronic hepatitis B infection. Gastroenterology 111:183-192. (Pubitemid 26226898)
15. Mun HS, Lee SA, Jee Y, Kim H, Park JH, Song BC, Yoon JH, Kim YJ, Lee HS, Hyun JW, Hwang ES, Kook YH, Kim BJ. 2008. The prevalence of hepatitisBvirus preS deletions occurring naturally in Korean patients infected chronically with genotype C. J Med Virol 80:1189-1194. (Pubitemid 351705997)
16. Okamoto H, Wang Y, Tanaka T, Machida A, Miyakawa Y, MayumiM. 1993. Trans-complementation among naturally occurring deletion mutants of hepatitis B virus and integrated viral DNA for the production of viral particles with mutant genomes in hepatoma cell lines. J Gen Virol 74:407-414.
17. Song BC, Kim H, Kim SH, Cha CY, Kook YH, Kim BJ. 2005. Comparison of full length sequences of hepatitis B virus isolates in hepatocellular carcinoma patients and asymptomatic carriers of Korea. J Med Virol 75:13-19. (Pubitemid 39578784)
18. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF. 2001.Nomenclature for antiviral-resistanthuman hepatitis B virus mutations in the polymerase region. Hepatology 33:751-757. (Pubitemid 32185239)
19. Sugauchi F, Ohno T, Orito E, Sakugawa H, Ichida T, Komatsu M, Kuramitsu T, Ueda R, Miyakawa Y, MizokamiM. 2003. Influence of hepatitis B virus genotypes on the development of preS deletions and advanced liver disease. J Med Virol 70:537-544.
20. Tamura K, Dudley J, Nei M, Kumar S. 2007. MEGA4: Molecular Evolutionary Genetics Analysi (MEGA) software version 4.0. Mol Biol Evol 24:1596-1599. (Pubitemid 47236692)
21. Thompson JD, Higgins DG, Gibson TJ. 1994. CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22:4673-4680.
22. Villet S, PichoudC,Villeneuve JP, TrepoC, Zoulim F. 2006. Selection of a multiple drug-resistant hepatitis B virus strain in a livertransplanted patient. Gastroenterology 131:1253-1261. (Pubitemid 44515103)
23. Yang H, Qi X, Sabogal A,MillerM, Xiong S, Delaney WE. 2005. Crossresistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 10:625-633. (Pubitemid 41224954)
24. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. 2006. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 44:703-712. (Pubitemid 44433727)
25. Yuan TT, Lin MH, Chen DS, Shih C. 1998a. A defective interferencelike phenomenon of human hepatitis B virus in chronic carriers. J Virol 72:578-584. (Pubitemid 28048874)
26. Yuan TT, Lin MH, Qiu SM, Shih C. 1998b. Functional characterization of naturally occurring variants of human hepatitis B virus containing the core internal deletion mutation. J Virol 72:2168-2176. (Pubitemid 28100773)